For 22 years, Jason Mazzola’s life was defined by a genetic condition that can cause autism and intellectual disability. Then he started taking an experimental drug.
In a large study, the experimental drug donanemab slowed the progression of Alzheimer's by about 35%. That's slightly better than the drug Leqembi, which was fully approved by the FDA on July 6.
